(P 529) THE MUSCULOSKELETAL TUMOR REGISTRY -- 2023 UPDATE AND OUTLOOK

Objective: The Musculoskeletal Tumor Registry (MsTR) is a collaboration between the Musculoskeletal Tumor Society (MSTS) and American Academy of Orthopaedic Surgeons (AAOS) to prospectively record oncologic and functional outcomes in patients treated surgically for pelvic and extremity bone and soft tissue sarcoma, as well as metastatic bone disease (MBD). The focus of 2022 was on completing the development of the sarcoma module. At the end of the 2022 calendar year, five institutions are submitting data for collection. Overall, there are currently 28 contracted institutions in various stages of registry framework implementation for expansion of the MsTR.

Methods: The goals for 2023 include: 1) Refinement of the development of the sarcoma modules, 2) Confirm data accuracy and completeness of the sarcoma module inputs, 3) Prioritize grant funding and opportunity for nested clinical trial infrastructure, 4) Continue to increase awareness and enrollment of sarcoma centers, 5) Dissemination of data to sarcoma-relevant organizations. The highest priority is to perform an extensive audit of the collected data in order to ensure integrity related to accuracy, informative, relevance, and parsimony. This is a critical step toward the ultimate goal of reporting reliable expectations and comparisons of oncologic and patient-reported outcomes.

Results: The ideal mechanism for data collection is still being explored throughout the AAOS family of registries, with analytics assessing manually-entered inputs against automated abstracted inputs. To date, all institutions currently submitting have been on the Epic HER platform. Analytical strategies include utilization of Epic for direct assistance, third party contracting, internal analysis through the AAOS Registry Analytics Institute or within a collaborating institution, or providing the option for REDCap entry.

Conclusion: The registry effort continues to progress and 2023 is already yielding significant developments in data auditing, further credentialing, and expansion to interested sarcoma centers. Further efforts are ongoing towards grant proposals and nested clinical trials, publications, and development of REDCap as an alternative data entry platform. Additional development and refinement of smartforms within Epic focus upon minimizing manual data entry while maintaining data integrity.